Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium
Using Sapu Nano's proprietary Deciparticle™ technology, Sapu-003 delivers everolimus intravenously SYDNEY, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) — via IBN – Sapu Nano today announced the presentation of its poster, "Sapu-003: Novel Intravenous Deciparticl
(Financial Post, 2025-10-08T12:32:34Z)